Chugai Pharmaceutical Co. applied Monday to the Health, Labor and Welfare Ministry for special approval of the use of antibody cocktail Ronapreve to prevent the onset of symptoms in COVID-19 patients' family members and close contacts.
Ronapreve is already used to treat COVID-19 patients who are suffering mild to moderate symptoms.
The company requested special approval to shorten the review period.
In a clinical trial conducted overseas on people in close contact with infected patients, use of the cocktail was found to reduce the risk of the onset of symptoms by 81%.
The company also applied for subcutaneous administration of the drug in addition to the current intravenous administration.
Read more from The Japan News at https://japannews.yomiuri.co.jp/
